EGFR and non-small cell lung carcinoma: The combination of amivantamab and lazertinib versus lazertinib monotherapy will be assessed in a phase I/IIb expansion study CHRYSALIS-2 in several cohorts of NSCLC patients including cohort A: classical EGFR mutations with progression on osimertinib, cohort B: EGFR exon 20 insertions with progression on prior therapy, and cohort C: patients with rare EGFR mutations (e.g S768I, L861Q, G719X) [87].